Nutriband Inc Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)1.78 Intrinsic Value $3.96median of 2 methodsbased on filings through 31 Jul 2026 Market Price $7.36Price as of 1 Oct 2026 OvervaluedIntrinsic value is 46% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $89.5M Enterprise Value $86.2M Shares Outstanding 12.6M diluted Next Earnings Date15 Dec 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary NutriBand Inc. is a clinical-stage pharmaceutical company focused on developing its proprietary AVERSA abuse-deterrent transdermal technology, with its lead product candidate being AVERSA Fentanyl. While the technology holds significant market potential (estimated peak US sales of $80M to $200M) and is backed by a strong development partnership with Kindeva Drug Delivery, the company remains pre-commercial with minimal revenues and high operating losses. The planned divestiture of 90% of its Pocono subsidiary for $5 million was officially terminated on February 13, 2026, after the buyer failed to pay required late fees, meaning Pocono remains under Nutriband's control. Near-term stock performance is highly dependent on regulatory milestones, specifically the IND filing and subsequent Human Abuse Potential clinical trials. Given the high-risk nature of early-stage biotech and the lack of immediate commercial catalysts, a Hold recommendation is appropriate. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$15.00 Mean target$15.00 High · most bullish analyst$15.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The FDA requests additional preclinical data, delaying the IND filing or clinical trials. Cash burn accelerates faster than expected, forcing dilutive equity raises if the Pocono transaction faces delays or structural issues. Base CaseCentral scenario The company successfully files its IND and initiates the Human Abuse Potential clinical study for AVERSA Fentanyl. Following the termination of the Pocono divestiture in February 2026, the company relies on its existing cash runway, potential warrant exercises, and strategic partnerships to fund operations through clinical milestones, stabilizing the stock price around consensus targets. Bull CaseUpside scenario Successful commercialization of AVERSA Fentanyl through its exclusive partnership with Kindeva Drug Delivery, capturing a significant share of the $80M - $200M peak annual US sales potential, and expanding the AVERSA technology platform to other transdermal drugs. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |